Physician profile
Lingling Du
NPI 1003103532
$172,847.65
in general payments reported to CMS, 2019-2025
27 companies · $79K in 2025
The $79K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $10K · 2023: $31K · 2024: $53K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $91K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $27K · Travel and Lodging: $22K · Consulting Fee: $15K · Food and Beverage: $5,386 · Honoraria: $2,450 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $91,126.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $27,072.50 |
| Travel and Lodging | $21,666.60 |
| Consulting Fee | $14,678.50 |
| Food and Beverage | $5,385.55 |
| Honoraria | $2,450.00 |
| Education | $134.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $90,169.65 | 2022-2025 | Therasphere Y90 Glass Microspheres 10 Gbq, Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial), General - Interventional Oncology |
| Exelixis INC. | $40,789.18 | 2022-2025 | Cabometyx |
| Ipsen Biopharmaceuticals, INC | $20,614.21 | 2022-2024 | Onivyde, Somatuline Depot |
| Astrazeneca Pharmaceuticals LP | $6,861.84 | 2022-2025 | Enhertu, Imjudo |
| Sirtex Medical INC | $4,548.48 | 2025 | Sir-Spheres Microspheres |
| E.R. Squibb & Sons, L.L.C. | $2,602.47 | 2023-2025 | Krazati, Opdivo |
| Beone Medicines USA, INC. | $2,007.72 | 2025 | Brukinsa, Tevimbra |
| Array Biopharma INC | $1,890.00 | 2022 | |
| Incyte Corporation | $1,226.04 | 2023-2025 | Zynyz, Pemazyre |
| Eisai INC. | $867.00 | 2023-2025 | |
| Genentech USA, INC. | $273.23 | 2022-2024 | Tecentriq |
| Novartis Pharmaceuticals Corporation | $264.92 | 2022-2025 | |
| Intera Oncology, INC | $201.88 | 2025 | Intera |
| Trisalus Life Sciences, INC. | $159.88 | 2023 | Trinav Infusion System |
| Tersera Therapeutics LLC | $83.30 | 2025 | Xermelo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $57.00 | 2024 | Jemperli |
| Astellas Pharma US INC | $56.99 | 2024-2025 | Vyloy, Xospata |
| Janssen Biotech, INC. | $47.90 | 2022 | |
| Masimo Corporation | $39.34 | 2022 | |
| Daiichi Sankyo INC. | $25.80 | 2024 | Enhertu |
| Abbvie INC. | $21.06 | 2023 | Creon |
| Takeda Pharmaceuticals U.S.A., INC. | $20.25 | 2025 | Fruzaqla |
| Beigene USA, INC. | $19.51 | 2025 | Brukinsa |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lingling Du listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.